June 1, 2024Journal of Clinical Oncology

Phase 1/2 study of XTX202, a tumor-activated IL-2βγ, in advanced solid tumors.

View Full Paper

Ask AI

Bookmark

Authors

JCJad ChahoudOrlando Health YZYousef ZakhariaRutgers, The State University of New Jersey MMMeredith McKeanSarah Cannon

Discussion

Member takes

Implication

Randomized trial demonstrates tumor-selective activation and disease control with XTX202 in advanced solid tumors, highlighting potential for combination immunotherapy.

Key Points

XTX202 generated tumor-selective activation with negligible peripheral release, driving sustained disease control without expanding regulatory t cells.
Disease control reached 80% at the recommended dose, and treatment-related cytokine release syndrome occurred in 2% of all treated cohorts.
Clinical evaluation across Phase 1 and Phase 2 cohorts demonstrates outpatient feasibility, supporting novel combination therapies in renal cell carcinoma and melanoma.

Cite This Study

Chahoud et al. (2024) studied this question.

synapsesocial.com/papers/68e66dc6b6db6435875f8a2a https://doi.org/10.1200/jco.2024.42.16_suppl.2595

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial demonstrates tumor-selective activation and disease control with XTX202 in advanced solid tumors, highlighting potential for combination immunotherapy.

Phase 1/2 study of XTX202, a tumor-activated IL-2βγ, in advanced solid tumors.

Discussion

Member takes

Implication

Key Points

Cite This Study

Phase 1/2 study of XTX202, a tumor-activated IL-2βγ, in advanced solid tumors.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider